US 11,986,466 B2
Methods of treating solid tumors with CCR2 antagonists
James J. Campbell, San Jose, CA (US); Rajinder Singh, Belmont, CA (US); Samuel Hwang, Oakland, CA (US); and Xuesong Wu, Oakland, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., Mountain View, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Dec. 21, 2020, as Appl. No. 17/128,500.
Application 17/128,500 is a continuation of application No. 16/358,329, filed on Mar. 19, 2019, abandoned.
Application 16/358,329 is a continuation in part of application No. 16/241,391, filed on Jan. 7, 2019.
Claims priority of provisional application 62/614,923, filed on Jan. 8, 2018.
Prior Publication US 2021/0346361 A1, Nov. 11, 2021
Int. Cl. A61K 31/4433 (2006.01); A61K 31/496 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/4433 (2013.01) [A61K 31/496 (2013.01); A61K 39/39533 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 4 Claims
 
1. A method of treating cutaneous T cell lymphoma (CTCL), said method comprising administering to a subject in need thereof an effective amount of a Chemokine Receptor 2 (CCR2) antagonist, wherein said CCR2 inhibitor is selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.